Mylan generic launch adds to Teva competition

10 March 2017

Hot on the heels of another generics giant, Netherlands-based Mylan (Nasdaq: MYL) has launched a generic version of Pristiq (desvenlafaxine) extended-release tablets in the USA

Earlier this month the Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) announced that, together with India’s Lupin (LOPN: BSE), it was launching a generic of the serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder.

Pristiq, which is marketed by US pharma giant Pfizer (NYSE: PFE), had US sales of approximately $853 million for the 12 months ending January 31, 2017, according to IMS Health.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK